C10770: AKT1 and AKT2 KO CellsValue Proposition: Cell Lines
AKT1-/- (D3A8G5) in HCT116
AKT1-/- (H1D1A12) in HCT116
AKT1-/-, AKT2-/- (HDK1-B2-F12-E5) in HCT116
AKT1-/-, AKT2-/- (HDK2-E1-B2-G3) in HCT116
AKT2-/- (A10A5C6) HCT116 in HCT116
AKT2-/- (C12B8B5) HCT116 in HCT116
AKT1-/- (D6D7A12) in DLD1
AKT1-/- (G10C3C5) in DLD1
AKT1-/-, AKT2-/- (DDK3-C2-G4-H2) in DLD1
AKT1-/-, AKT2-/- (DDK4-E11-A3-A8) in DLD1
Technical Details:
JHU scientists have developed several AKT knockouts in human colorectal cancer cell lines HCT116 and DLD1. The AKT protein family, consisting of Akt1, Akt2, and Akt3, plays an important role in mammalian cellular signaling. Members of the family are also called protein kinases B (PKB).
Akt1 is involved in cellular survival pathways, by inhibiting apoptotic processes. Since Akt1 can block apoptosis, and thereby promote cell survival, it has been implicated as a major factor in many types of cancer.
Akt2 is an important signaling molecule in the Insulin signaling pathway but has also been associated with a malignant phenotype of a subset of human colorectal cancers.
Looking for Partners:
The cell lines described can be used in screens for novel molecules that target the Akt pathway in human cancer cells to confirm the specificity of drugs discovered through other approaches. Such drugs can potentially be used as chemotherapeutic or chemopreventive agents.
